|Bid||49.76 x 1200|
|Ask||49.78 x 1300|
|Day's Range||49.62 - 49.80|
|52 Week Range||44.88 - 57.94|
|PE Ratio (TTM)||20.99|
|Forward Dividend & Yield||0.63 (1.29%)|
|1y Target Est||61.78|
Fresenius Medical Care AG said it completed the divestment of Sound Inpatient Physicians Holdings, selling the business to an investment consortium led by Summit Partners. The German company, which provides dialysis services, said the divestment will bolster its net income by about $752 million.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More...
Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company.
Durham-based Humacyte has landed a $150 million equity investment from Fresenius Medical Care. According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities. “Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson.
BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.
Moody's Investors Service (Moody's) assigned a B1 Corporate Family Rating (CFR) and B1-PD Probability of Default Rating to Ironman Merger Sub, LLC. Ironman Merger Sub, LLC will become Sound Inpatient Physician Holdings, LLC ("Sound") immediately following the $2.2 billion acquisition of the company. Sound will be acquired by Summit Partners and OptumHealth Holdings, LLC ("OptumHealth") from Fresenius Medical Care AG & Co. KGaA (Baa3 stable). OptumHealth is owned by health insurance company UnitedHealth Group, Inc. (A3 stable).
Cara said it has licensed worldwide rights — except in the U.S., Japan and South Korea — to commercialize Korsuva injection with VFMCRP, a joint venture between Vifor Pharma and Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS). The deal provides for a $50-million upfront cash payment to Cara and an equity investment of $20 million via share sales at $17 apiece.
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co KGaA (XTRA:FME), a large-cap worth €26.04B. Risk-averse investors who are attracted toRead More...
JERUSALEM , April 30, 2018 /PRNewswire/ -- RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS® critical care urine monitoring system ...
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
The ECB kept its main refinancing rate, and rates on marginal lending facility and deposit facility at unchanged at 0%, 0.258% and -0.4%, respectively.
U.S. generic drugmaker Akorn (AKRX.O) is taking former suitor Fresenius (FREG.DE) to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $4.75 billion takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.
dropped its planned $5 billion takeover of the generic drugmaker after a probe into possible data breaches by the U.S. Food & Drug Administration. Fresenius said it found "material" breaches of FDA1 data integrity rules as part of its own investigation into allegations levelled against the Lake Forest, Ill.-based Akorn earlier this year and offered to delay its proposed takeover if the group could supply information that would allow Fresenius to reconsider. The Germany company said Akorn declined that offer.
Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business. Germany's Fresenius on Sunday cited evidence of misconduct in the target's reporting of drug development data to U.S. healthcare regulators, but analysts pointed to investor relief because Akorn's business had deteriorated. "Investors will likely be pleased that the merger agreement has been terminated, given the substantial decline in Akorn’s operating performance since the agreement was signed last April," said Berenberg analyst Tom Jones.